ADAURA and the Evolving Role of Targeted Therapy
Podcast | English | 40 Min
Image For Activity Cover
Credit
No Credit Offered
Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial. ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR-positive NSCLC. While we have seen targeted therapy in this space, ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.

Podcast Hosts:

  • Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  
  • Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

  • Roy Herbst, MD, PhD, Chief, Medical Oncology, Yale Cancer Center, New Haven, CT, USA
Powered By